Latest Insider Transactions at Ardelyx, Inc. (ARDX)
This section provides a real-time view of insider transactions for Ardelyx, Inc. (ARDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARDELYX, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARDELYX, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
2,243
-1.46%
|
$8,972
$4.79 P/Share
|
|
Nov 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,941
-1.64%
|
$19,764
$4.79 P/Share
|
|
Nov 20
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,366
-2.33%
|
$29,464
$4.79 P/Share
|
|
Nov 20
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
31,980
-2.65%
|
$127,920
$4.79 P/Share
|
|
Nov 20
2024
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,260
-1.77%
|
$21,040
$4.79 P/Share
|
|
Nov 20
2024
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
4,941
-1.55%
|
$19,764
$4.79 P/Share
|
|
Nov 20
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
7,046
-3.66%
|
$28,184
$4.79 P/Share
|
|
Nov 13
2024
|
David M Mott Director |
BUY
Open market or private purchase
|
Direct |
215,868
+13.15%
|
$863,472
$4.62 P/Share
|
|
Nov 11
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
2,743
-0.23%
|
$10,972
$4.9 P/Share
|
|
Nov 06
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
27,171
-15.03%
|
$163,026
$6.1 P/Share
|
|
Nov 06
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
27,171
+13.07%
|
$54,342
$2.32 P/Share
|
|
Nov 04
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
27,172
-15.03%
|
$135,860
$5.95 P/Share
|
|
Nov 04
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
27,172
+13.07%
|
$54,344
$2.32 P/Share
|
|
Oct 28
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.02%
|
$125,000
$5.91 P/Share
|
|
Oct 28
2024
|
Michael Raab President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+1.98%
|
$0
$0.99 P/Share
|
|
Oct 11
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-0.62%
|
$45,000
$6.01 P/Share
|
|
Sep 27
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
49,564
-14.1%
|
$297,384
$6.92 P/Share
|
|
Sep 26
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.25%
|
$18,000
$6.07 P/Share
|
|
Sep 13
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
5,312
-3.34%
|
$31,872
$6.26 P/Share
|
|
Sep 11
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
35,000
-2.79%
|
$175,000
$5.61 P/Share
|
|
Sep 11
2024
|
Michael Raab President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+2.71%
|
$0
$0.99 P/Share
|
|
Aug 27
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-0.61%
|
$45,000
$6.22 P/Share
|
|
Aug 20
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,412
-2.3%
|
$37,060
$5.86 P/Share
|
|
Aug 20
2024
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,289
-1.76%
|
$26,445
$5.86 P/Share
|
|
Aug 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
22,757
-6.44%
|
$113,785
$5.93 P/Share
|
|
Aug 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,969
-1.39%
|
$24,845
$5.86 P/Share
|
|
Aug 20
2024
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
4,969
-1.53%
|
$24,845
$5.86 P/Share
|
|
Aug 20
2024
|
Robert Ora Felsch Officer |
SELL
Open market or private sale
|
Direct |
3,567
-3.75%
|
$17,835
$5.86 P/Share
|
|
Aug 20
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
7,089
-3.55%
|
$35,445
$5.86 P/Share
|
|
Aug 20
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
32,225
-2.56%
|
$161,125
$5.86 P/Share
|
|
Aug 20
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
20,507
+10.28%
|
$0
$0.99 P/Share
|
|
Aug 16
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
20,000
-5.31%
|
$100,000
$5.94 P/Share
|
|
Aug 12
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
1,229
-0.1%
|
$6,145
$5.71 P/Share
|
|
Aug 08
2024
|
Eric Duane Foster Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,000
+50.0%
|
-
|
|
Jul 29
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.32%
|
$150,000
$5.64 P/Share
|
|
Jul 29
2024
|
Michael Raab President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.27%
|
$0
$0.99 P/Share
|
|
Jul 15
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-0.59%
|
$37,500
$5.97 P/Share
|
|
Jun 28
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
2,310
-0.18%
|
$13,860
$6.59 P/Share
|
|
Jun 21
2024
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
38,000
-10.49%
|
$190,000
$5.96 P/Share
|
|
Jun 14
2024
|
Richard J Rodgers Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,204
+4.65%
|
-
|
|
Jun 14
2024
|
William C Bertrand Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,023
+4.58%
|
-
|
|
Jun 14
2024
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,322
+1.41%
|
-
|
|
Jun 13
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
35,000
-2.68%
|
$210,000
$6.65 P/Share
|
|
Jun 13
2024
|
Michael Raab President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+2.61%
|
$0
$0.99 P/Share
|
|
Jun 05
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
145,000
-16.66%
|
$1,015,000
$7.12 P/Share
|
|
Jun 05
2024
|
Laura A Williams Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+17.63%
|
$200,000
$2.75 P/Share
|
|
Jun 03
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
17,872
-10.13%
|
$125,104
$7.0 P/Share
|
|
May 29
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-0.59%
|
$45,000
$6.72 P/Share
|
|
May 21
2024
|
Susan Rodriguez Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,703
-1.47%
|
$46,921
$7.81 P/Share
|
|
May 21
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
2,198
-1.23%
|
$15,386
$7.81 P/Share
|